Pluristem Therapeutics Inc. (NASDAQ:PSTI) Expected to Post Earnings of -$0.80 Per Share

Brokerages expect that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will report earnings of ($0.80) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics also reported earnings per share of ($0.80) during the same quarter last year. The firm is scheduled to announce its next earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Pluristem Therapeutics will report full-year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($2.90) to ($2.08). For the next year, analysts expect that the business will post earnings of ($1.80) per share. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Pluristem Therapeutics.

A number of equities analysts recently issued reports on PSTI shares. ValuEngine downgraded Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. LADENBURG THALM/SH SH started coverage on Pluristem Therapeutics in a report on Monday, July 22nd. They issued a “buy” rating for the company. Finally, Zacks Investment Research raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Pluristem Therapeutics presently has an average rating of “Buy” and a consensus price target of $27.50.



A number of institutional investors and hedge funds have recently made changes to their positions in the stock. United Capital Financial Advisers LLC boosted its holdings in Pluristem Therapeutics by 37.8% in the second quarter. United Capital Financial Advisers LLC now owns 85,733 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 23,533 shares in the last quarter. Jane Street Group LLC lifted its stake in Pluristem Therapeutics by 28.1% in the second quarter. Jane Street Group LLC now owns 153,322 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 33,630 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Pluristem Therapeutics in the second quarter valued at approximately $231,000. Nikko Asset Management Americas Inc. lifted its stake in Pluristem Therapeutics by 102.8% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,882,401 shares of the biotechnology company’s stock valued at $1,168,000 after buying an additional 954,161 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Pluristem Therapeutics by 107.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,882,401 shares of the biotechnology company’s stock valued at $1,168,000 after buying an additional 974,306 shares during the last quarter. 94.39% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ PSTI traded up $0.05 during midday trading on Wednesday, hitting $3.68. 16,700 shares of the company’s stock were exchanged, compared to its average volume of 54,355. Pluristem Therapeutics has a twelve month low of $3.24 and a twelve month high of $12.50. The company has a market cap of $57.22 million, a PE ratio of -1.47 and a beta of 1.05. The firm’s fifty day simple moving average is $3.90 and its 200-day simple moving average is $1.97.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Recommended Story: What is cost of equity?

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.